World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
87
Citations
37777
World Ranking
13442
National Ranking
6836

Mikhail Kosiborod publications per year

2001: 1 publications 2002: 3 publications 2003: 2 publications 2004: 2 publications 2005: 6 publications 2006: 4 publications 2007: 9 publications 2008: 9 publications 2009: 14 publications 2010: 13 publications 2011: 9 publications 2012: 13 publications 2013: 17 publications 2014: 33 publications 2015: 16 publications 2016: 20 publications 2017: 32 publications 2018: 38 publications 2019: 40 publications 2020: 62 publications 2021: 76 publications 2022: 2 publications 2023: 0 publications 2024: 0 publications 2025: 22 publications
2001 2025

443 publications in total across all disciplines

Mikhail Kosiborod publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Mikhail Kosiborod sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 435 publications — 46th percentile

46% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Mikhail Kosiborod D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Mikhail Kosiborod sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 87 D-Index — 34th percentile

34% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Mikhail Kosiborod is affiliated with the University of Missouri-Kansas City in the United States and specializes in medical research with a focus on endocrinology, diabetes, metabolism, and cardiology. Their scholarly output consists of over a thousand publications, primarily centered on diabetes treatment and management, as well as heart failure treatment.

Their research spans several interconnected fields, including:

  • Endocrinology, Diabetes and Metabolism
  • Cardiology and Cardiovascular Medicine
  • Surgery
  • Molecular Biology
  • Pulmonary and Respiratory Medicine

Major topics in their work comprise:

  • Diabetes Treatment and Management
  • Heart Failure Treatment and Management
  • Cardiovascular Function and Risk Factors
  • Pancreatic Function and Diabetes
  • Diabetes Management and Research
  • Metabolism, Diabetes, and Cancer
  • Potassium and Related Disorders

Recent notable papers by Kosiborod include:

  • "Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity," 2023, published in the New England Journal of Medicine

Other significant papers relevant to their research area, which they coauthored or collaborated on within the broader community, include:

  • "Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction," 2022, New England Journal of Medicine
  • "Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease," 2020, New England Journal of Medicine
  • "Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association," 2023, Circulation
  • "SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials," 2022, The Lancet

Frequent co-authors working closely with Kosiborod include:

  • John J.V. McMurray
  • Scott D. Solomon
  • Pardeep S. Jhund
  • Silvio E. Inzucchi
  • Felipe A. Martínez

Publication venues where Kosiborod's contributions appear frequently include:

  • Circulation
  • Journal of the American College of Cardiology
  • European Journal of Heart Failure
  • JACC Heart Failure
  • European Heart Journal

Best Publications

  • Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

    John J.V. McMurray;Scott D. Solomon;Silvio E. Inzucchi;Lars Køber

  • Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

    Adrian F Hernandez;Jennifer B Green;Salim Janmohamed;Ralph B D'Agostino

  • Management of Hyperglycemia in Hospitalized Patients in Non-Critical Care Setting: An Endocrine Society Clinical Practice Guideline

    Guillermo E. Umpierrez;Richard Hellman;Mary T. Korytkowski;Mikhail Kosiborod

  • Excess Mortality among Persons with Type 2 Diabetes

    Mauro Tancredi;Annika Rosengren;Ann-Marie Svensson;Mikhail Kosiborod

  • The obesity paradox: body mass index and outcomes in patients with heart failure.

    Jeptha P. Curtis;Jared G. Selter;Yongfei Wang;Saif S. Rathore

  • Glycemic Control and Excess Mortality in Type 1 Diabetes

    Marcus Lind;Ann-Marie Svensson;Mikhail Kosiborod;Soffia Gudbjörnsdottir

  • Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors).

    Mikhail Kosiborod;Matthew A. Cavender;Alex Z. Fu;John P. Wilding

  • Admission glucose and mortality in elderly patients hospitalized with acute myocardial infarction: implications for patients with and without recognized diabetes.

    Mikhail Kosiborod;Saif S. Rathore;Silvio E. Inzucchi;Frederick A. Masoudi

  • Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.

    Deepak L. Bhatt;Michael Szarek;Bertram Pitt;Christopher P. Cannon

  • Trends in length of stay and short-term outcomes among Medicare patients hospitalized for heart failure, 1993-2006.

    Héctor Bueno;Joseph S. Ross;Yun Wang;Jersey Chen

  • Contemporary Incidence, Predictors, and Outcomes of Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Interventions : Insights From the NCDR Cath-PCI Registry

    Thomas T. Tsai;Thomas T. Tsai;Uptal D. Patel;Tara I. Chang;Kevin F. Kennedy

  • Glucometrics in Patients Hospitalized With Acute Myocardial Infarction Defining the Optimal Outcomes-Based Measure of Risk

    Mikhail Kosiborod;Silvio E. Inzucchi;Harlan M. Krumholz;Lan Xiao

  • Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update

    Shannon M. Dunlay;Michael M. Givertz;David Aguilar;Larry A. Allen

  • The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial.

    Michael E Nassif;Sheryl L Windsor;Barry A Borlaug;Dalane W Kitzman

  • Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study

    Mikhail Kosiborod;Carolyn S.P. Lam;Shun Kohsaka;Dae Jung Kim;Dae Jung Kim

  • Worsening renal function: What is a clinically meaningful change in creatinine during hospitalization with heart failure?

    Grace L. Smith;Viola Vaccarino;Mikhail Kosiborod;Judith H. Lichtman

  • Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes

    Mark C Petrie;Subodh Verma;Kieran F Docherty;Silvio E Inzucchi

  • Relationship between spontaneous and iatrogenic hypoglycemia and mortality in patients hospitalized with acute myocardial infarction.

    Mikhail Kosiborod;Silvio E. Inzucchi;Abhinav Goyal;Harlan M. Krumholz

  • Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials

    Jay S. Skyler;Richard Bergenstal;Robert O. Bonow;John Buse

  • Cardiovascular Outcomes and Mortality in Type 2 Diabetes with Associated Cardio-Renal-Metabolic Comorbidities

    Suzanne V. Arnold;Phillip R. Hunt;Hungta Chen;Sharon Maclachlan

Frequent Co-Authors

John A. Spertus
John A. Spertus University of Missouri–Kansas City
Silvio E. Inzucchi
Silvio E. Inzucchi Yale University
Darren K. McGuire
Darren K. McGuire The University of Texas Southwestern Medical Center
Marc S. Sabatine
Marc S. Sabatine Brigham and Women's Hospital
Scott D. Solomon
Scott D. Solomon Brigham and Women's Hospital
Frederick A. Masoudi
Frederick A. Masoudi University of Colorado Anschutz Medical Campus
John J.V. McMurray
John J.V. McMurray University of Glasgow
Niklas Hammar
Niklas Hammar Karolinska Institute
Harlan M. Krumholz
Harlan M. Krumholz Yale University
Lars Køber
Lars Køber Copenhagen University Hospital

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in expanding their career options beyond traditional medical school, there are a range of online degrees and healthcare pathways to consider. Many practicing nurses pursue advancement through affordable degree completion programs, such as cheap rn to bsn online programs designed to boost credentials and open doors to leadership roles.

Individuals without a nursing background can explore online direct entry msn programs for non-nurses, allowing them to quickly pivot into advanced nursing careers. These programs provide a fast-track option for those holding a non-nursing bachelor’s degree, helping ease entry into the healthcare sector.

If you’re concerned about program competitiveness, there are nursing schools with high acceptance rates that provide accessible pathways into the field. For those interested in healthcare administration, medical billing and coding schools that accept financial aid offer online study options, helping students begin a stable career without a heavy financial burden.

Best Scientists Citing Mikhail Kosiborod

Trending Scientists

Recently Published Articles